Studies have also confirmed that the mammalian target of rapamycin (mTOR) pathway is related to the genesis and progression of kidney cancer [8, 9], which paves the way for new drugs for ccRCC. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.